{"id":"NCT03103152","sponsor":"Queen Mary University of London","briefTitle":"A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression","officialTitle":"PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-12","primaryCompletion":"2020-03-31","completion":"2020-03-31","firstPosted":"2017-04-06","resultsPosted":"2023-03-29","lastUpdate":"2023-03-29"},"enrollment":104,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Prostate Cancer"],"interventions":[{"type":"DRUG","name":"High dose Aspirin & Vitamin D","otherNames":["Aspirin - acetylsalicylic acid","Vitamin D - Vigantol® Oil"]},{"type":"DRUG","name":"High dose Aspirin, Vitamin D placebo","otherNames":["Aspirin - acetylsalicylic acid","Vitamin D placebo - Miglyol®812 Oil"]},{"type":"DRUG","name":"Low dose Aspirin , Vitamin D","otherNames":["Aspirin - acetylsalicylic acid","Vitamin D - Vigantol® Oil"]},{"type":"DRUG","name":"Low dose Aspirin, Vitamin D placebo","otherNames":["Aspirin - acetylsalicylic acid","Vitamin D placebo - Miglyol®812 Oil"]},{"type":"DRUG","name":"Aspirin Placebo, Vitamin D","otherNames":["Vitamin D - Vigantol® Oil"]},{"type":"DRUG","name":"Aspirin placebo, Vitamin D placebo","otherNames":["Aspirin Placebo, Vitamin D","Vitamin D placebo - Miglyol®812 Oil"]}],"arms":[{"label":"High dose Aspirin & Vitamin D","type":"EXPERIMENTAL"},{"label":"High dose Aspirin, Vitamin D placebo","type":"EXPERIMENTAL"},{"label":"Low dose Aspirin , Vitamin D","type":"EXPERIMENTAL"},{"label":"Low dose Aspirin, Vitamin D placebo","type":"PLACEBO_COMPARATOR"},{"label":"Aspirin Placebo, Vitamin D","type":"EXPERIMENTAL"},{"label":"Aspirin placebo, Vitamin D placebo","type":"EXPERIMENTAL"}],"summary":"To demonstrate the acceptability and feasibility of recruitment to a randomised chemoprevention study of standard (300mg) or low dose (100mg) aspirin vs. placebo and/or Vitamin D3 vs. placebo in patients enrolled on an Active Surveillance programme for prostate cancer.","primaryOutcome":{"measure":"Rate of Patient Recruitment to a Randomised Chemoprevention Study in Men Enrolled on an Active Surveillance Programme for Prostate Cancer. Number Accrued Per Month.","timeFrame":"12 months","effectByArm":[{"arm":"High Dose Aspirin & Vitamin D","deltaMin":17,"sd":null},{"arm":"High Dose Aspirin, Vitamin D Placebo","deltaMin":16,"sd":null},{"arm":"Low Dose Aspirin , Vitamin D","deltaMin":19,"sd":null},{"arm":"Low Dose Aspirin, Vitamin D Placebo","deltaMin":18,"sd":null},{"arm":"Aspirin Placebo, Vitamin D","deltaMin":16,"sd":null},{"arm":"Aspirin Placebo, Vitamin D Placebo","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":17},"commonTop":["Cold","Headache","Diarrhoea","Nose Bleed","Sore Throat"]}}